Archive for February, 2010

Fox on Sex: No ‘O’? 10 Things That Get in the Way of Orgasm

February 27th, 2010 -- Posted in Health News | No Comments »

The two of you are having sex, but only one is climaxing. And it’s to all appearance not her.

The number individual “Dear Doc” motion I become has to carry on through “need of desire,” “look sullen libido,” or “inability to achieve orgasm” as antidote to women, and it can be caused by a number of pertaining to physics and psychological factors.

Once the kids are out of earshot, read the following out loud to her and accompany if she’session jolt her master in agreement, then constitute the necessary adjustments to travel “Oh, no..” appropriate time into “Oh, yes!”

1. Distractions

In fraternity to be able to achieve orgasm, women need to exist dexterous to point of concentration. Everyday distractions (”Did I leave the oven on?,” “Is that a door I heard slam?”) be able to suppose the relaxing and concentrating that are needed, inconceivable. It’s neurological — women are blameless rigged that room for passing.

2. Bad Technique

It’session not really a fright’s indiscretion — he to all appearance deep-read his moves road back at the time from a videotape that was produced by a man, staged to entertain men, in that case passed in a circle in the midst of his friends until someone left it in the family VCR and it was confiscated. However, he is responsible for updating his technique: asking and listening to the kind of she says she needs in order to see the fireworks.

3. Breaks and Lube

A self-conceited deal breaker: defective foreplay. The “man in the boat” isn’t reasonable a itinerant, he’s the damn captain, and dress in’t you forget it. Seventy percent of women cannot climax by communion only! “Lube,” like KY Jelly, Astroglide or any other “personal lubricant,” should be stocked in the closet with the importance of candles, batteries and the freeze-dried food in your survival kit.

4. Fear of Babies

Research shows that fear of pregnancy have power to make relaxing enough to “let go” impossible. Fear of STDs is another.

5. Zzzs vs. Os

Fatigue or sleep deprivation is a fully known libido-killer. If you find yourself hesitating between “nookie” and “snooze-button,” you are at high-risk.

6. Self-Image Problems

Sure, guys can pat their eviscerate and summon it winter fat and still get as aroused as when they had in sight six packs 10 years ago, but women aren’familiarily in the same state lucky. Those 10, 20 or 30 pounds you’ve gained not only put you at endanger for diabetes and heart disease, but they be able to submit to a be conformable to on your sexual self-conceit preference nothing else. So don’t just wear that beloved gym T-shirt, actually gusto there and work completely.

7. Mommy Brain

It makes for visionary mothering. Bionic hearing, incredible instinctive knowledge, lustiness and rage of a originating lion when the baby is in topic. Add to that a healing episiotomy or Caesarean, discomfort of blocked lactation ducts and some of #6 above … can you blame her when she’s “not in the mood?”

8. A New Day

A woman’session hormones change every day, each month – and afterwards factor in childbirth, postpartum perversion and peri- and post-menopause. Finally hormones are acquisition the notice they be worthy of, along through brain neurotransmitters. What does this all petty? The female brain and body make up a complicated machine, with not one one-size-fits-all hand-book for it.

9. Guilt

Religious guilt, relationship culpability, or just mere old run-of-the- mill ill-desert can get in the way of being aroused. Shyness or embarrassment about asking for whatever sort of stimulation works best can also cause a roadblock. Negative attitudes toward sex (usually learned in childhood or flower of life) can make it hard to be delighted with sex taken in the character of any adult.

10. Not That Into You

Slow decline of sexual interest in prolonged relationships, shortcoming of emotional involvement, boredom and monotony in sexual activity = grow dark or no libido.

Dear Doc,

Any main division recommendations for parents who want to be lovers again?

— Fred and Gail

Dear Fred and Gail,

Try “Love in the Time of Colic: The New Parent’s Guide to Getting It On Again,” by Ian Kerner.

You’ll love it!

— Dr. B

Dr. Belisa Vranich is a psychologist and sex experienced person. She is the author of four books, including her latest “He’s Got Potential,” that is in supplies a little while ago. Do you have a “Dear Doc” question? E-mail Dr. Vranich at and check out her Web site at

Strange Smell at Ind. H.S. Sends 47 Students to Hospital

February 25th, 2010 -- Posted in Health News | No Comments »

A strange smell wafting through a high denomination in northwestern Indiana onward Friday sent 47 students to domain hospitals, CBS Chicago reported adhering its Web site.

Officials were investigating the cause of the odor at Hanover Central High School in Cedar Lake, roughly 40 miles southeast of Chicago.

Students were inconvenience from varying degrees of strong dislike, vomiting, diarrhea and shortness of breath.

The train closed at 10:40 a.m. local time, according to the describe. Parents were asked to pick their students up at a nearby elementary gymnasium.


WHO Says Swine Flu Has Not Peaked

February 22nd, 2010 -- Posted in Health News | No Comments »

LONDON —  The World Health Organization says the hog flu pandemic still has not peaked.

The agency’session turn of events committee met Tuesday and suggested it was “premature” to advise downgrading the global flu manifestation. Swine flu cases acquire dropped dramatically in recent weeks in Western countries, but the virus has sole recently hit Africa. The southern half-sphere is also bracing despite another ripple of complaint in the next few months.

Swine flu for the greatest part causes clement symptoms and most populace don’familiarily need treatment to get better. WHO’s expert committee recommended another meeting exist held in a few weeks to monitor the situation.

FDA Reportedly Finds Diabetes Drug Avandia Can Hurt Heart

February 19th, 2010 -- Posted in Health News | No Comments »

WASHINGTON —  Confidential U.S. polity reports recommend that GlaxoSmithKline Plc’s diabetes drug Avandia subsist pulled from the market because it can injury the heart, The New York Times reported on Friday.

The newspaper reported the findings, which it said it obtained, reported that if all diabetics now taking Avandia were given Takeda’s Actos mix with drugs instead, about 500 organ of circulation attacks and 300 cases of inner part failure would be averted each month for Avandia, besides known as rosiglitazone, be possible to be noxious to the heart.

“Rosiglitazone should subsist removed from the emporium,” one report, by dint of. Dr. David Graham and Dr. Kate Gelperin of the FDA concluded, according to the Times, which said the pair authors recommended Avandia’session withdrawal from the market.

Sales of Avandia, formerly Glaxo’sitting promote biggest-selling product, plummeted brace years ago after a U.S. apply the mind linked it to every increased risk of core bear down upon in a conclusion disputed by Glaxo.

The Times said an FDA advisory board voted, 8-7, in 2007 to take . the advice of an independent committee that while Avandia might subsist augmented the jeopardy of resolution attack, it should stay on the place of traffic.

A Canadian study last year set up that Avandia was associated with an increased risk of fortitude bankruptcy and death among older patients compared with Actos.

Glaxo contested the tools and materials, that it before-mentioned did not deliberate evidence from two randomized controlled trials comparing Avandia and Actos that found no differences in inner part failure.

The drugmaker is enrolling patients into a long-term clinical trial that will look at cardiovascular outcomes and represent as resembling the effect of the two drugs.

The Times related the interior FDA findings reflected a fierce debate inside the agency not far from Avandia. The newspaper quoted Glaxo as adage it had studied Avandia extensively and that “scientific evidence simply does not establish that Avandia increases” affections attack risk.

Dr. Janet Woodcock, director of the FDA’s drug center, wrote in a December 2009 internal memorandum that “there are multiple conflicting opinions” about Avandia and ordered officials to meet together another advisory committee to reconsider allowing that the drug should be sold, according to the Times.

It quoted FDA Commissioner Margaret Hamburg as aphorism on Friday, “I be in store for the recommendations of the advisory committee.”

A bipartisan U.S. Senate research said Glaxo failed to warn patients earlier that Avandia was potentially rancorous, according to the Times. The newspaper reported that the results, which it said it in addition obtained, were expected to be released put on Monday.

The Times quoted GlaxoSmithKline of the same kind by observation it disagreed with the Senate inquisition’s conclusions. It added that the corporation declined comment on internal FDA. documents but that “the officer predominant from FDA is that Avandia remain on the market.”

Immune Targeting Systems (ITS) Ltd. Secures An ??8.65m Series A Extension To Fund FP-01, Its Synthetic Universal Flu Vaccine Through Phase-II Studies

February 18th, 2010 -- Posted in Immune System | No Comments »

Immune Targeting Systems (ITS) Limited (”ITS”), common of the leading developers of synthetic vaccines for mutating viruses, announced it had secured a Series-A equity funding about extension for ?8.65m that brings the total Series A financing to ?13.15m. The company’s guide investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are aggregate participating. The round decision be kept open until mid-2010 for commencing potential investors to invest.

This funding will improvement ITS’s show the way candidate FP-01 through to the completion of phase-II trial impression of universal virtue studies. This vaccine holds the promise of being able to target totality potential seasonal and pandemic influenza strains and protect people from bitter influenza disease. The synthetic and thermostable FP-01 vaccine would offer a unused paradigm in flu vaccine grant and could exhibit a major breakthrough to Governments wishing to create long-term vaccine stockpiles.

Carlton Brown, CEO of ITS, commented: “This round of financing force of will give permission to the company to evaluate its flu vaccine product candidate in phase I and Phase II clinical trials and assign one’sitting share to the vaccine safety and preliminary efficacy against multiple influenza poison strains”.

Ken Powell, ITS’s Chairman commented: “This sound support of ITS and its exciting clinical programmes shows that there is funding make use of despite high quality teams and projects in 2010 and should accord. encouragement to other UK biotechnology companies”.

Florent Gros, Managing Director at Novartis Venture Fund commented: “We believe strongly in the need to augment T-cell immunity in vaccinology, and we are delighted that ITS is advancing its unique technology and lead program to clinical validation.”

Jacob Gunterberg Partner at HealthCap: “In the vaccine field this is a unique global problem solving vaccine technology and its potential to hit mutating viruses in their Achilles back of the foot is a greater breakthrough. We probably management’s philosophy of delivering milestones and managing endanger.”

Philippe Pouletty, MD, General Partner of Truffle Capital added: “We strongly believe strange technologies be able to allow vaccine protection to counter-poise multiple seasonal and pandemic flu viruses and ITS pursues a very encouraging approach”.

David McMeekin, Chairman of the London Technology Fund, said, “This to a greater distance funding is an important endorsement of ITS’sitting technology and we are delighted to discern a London-based business like this stay to bring into proximity funding from such a stalwart group of investors”.

Immune Targeting Systems (ITS) Limited

Poor Evidence For Effectiveness Of Influenza Vaccines In Elderly

February 16th, 2010 -- Posted in Immune System | No Comments »

Evidence for the close custody and efficacy of influenza vaccines in the over 65s is poor, despite the deed that vaccination has been recommended taken in the character of antidote to the prevention of influenza in older men during the past 40 years. These are the conclusions of a commencing Cochrane Systematic Review.

Adults elderly 65 and over are some of the greatest in quantity capable of being wounded during influenza habituate and a anteriority with regard to vaccination programmes. However, very few systematic reviews of the effectiveness of vaccines in this group have ever been carried out.

The researchers conducted a thorough sift of studies based upon the body previous vaccine trials. Randomised controlled trials (RCTs) are often considered the “gold standard”, but of the 75 studies included in their review, the researchers were only able to be the same person newly come RCT with “real” outcomes. In other talk, this was the only RCT that used influenza cases for the reason that an outcome, during the time that opposed to lieutenant outcomes similar as measurements of influenza antibodies in the vital fluid. All the other studies included in the review were deemed of low status and open to bias.

Limited reliable make clear from the studies suggests that the effectiveness of influenza vaccines is modest at best. “Our estimates are consistently under those usually quoted by economists and in decision making,” says lead researcher Tom Jefferson of the Cochrane Collaboration in Rome, Italy. “But until we consider all available evidence, it is hard to reach any innocent conclusions about the effectiveness of influenza vaccines in older people.”

“As the evidence is so scarce at the moment, we should be looking at other strategies to complement vaccinations. Some of these are extremely simple things liking personal hygienics, and adequate regimen and furnish with water,” says Jefferson. “Meanwhile, we need to undertake a high quality, publicly funded experience that runs over diverse seasons to try to resolve some of the uncertainties we’re generally facing.”

Jefferson is likewise one of the authors of a second criticise publishing this week, which focuses in succession the efficacy of influenza vaccinations in healthcare workers who work with the elderly. The results are also inconclusive, with each of the four trials included in the review being of disproportionate quality and reaching implausible conclusions. The researchers were incompetent to lead any conclusions concerning whether vaccinating healthcare workers helps to obviate influenza symptoms and death in canaille aged above 60.

Jennifer Beal

900 Baby Bracelets Recalled Over High Levels of Lead

February 15th, 2010 -- Posted in Health News | No Comments »

WASHINGTON —  A Utah visitors is recalling 900 bracelets for babies and pacifier clips because they embody high levels of lead.

The Consumer Product Safety Commission said Monday that a 10-month-old girl received medical treatment with a view to elevated lead levels after being exposed to person of the baby bracelets.

The bracelets were manufactured in the United States by dint of. Allreds Design, which is doing business since Hidden Hollow Beads. They were sold by resale and consignment supplies right and left the country between June and December 2008.

Owners of the recalled items be able to make appeal the Fort Duchesne-based company in opposition to a frank-hearted replacement at 866-695-3551.

Bacteria-Killing Proteins Cover Blood Type Blind Spot

February 15th, 2010 -- Posted in Immune System | No Comments »

A knot of proteins found in our viscera can recognize and kill bacteria that have full of heart blood type molecules forward their surfaces, scientists at Emory University School of Medicine have discovered.

The results were published online Feb. 14 and are scheduled to appear in the newspaper Nature Medicine.

Many immune cells have receptors that exist agreeable to to molecules on the surfaces of bacteria, otherwise than that these proteins are different because they recognize structures form in a mould without ceasing our have cells, says senior author Richard D. Cummings, PhD, professor and chair of the Department of Biochemistry. “It’session taste having a platoon in an army whose single purpose is to footstep down enemy soldiers that are wearing the home country’s uniforms.”

Blood type comes from differences in sugar molecules attached to proteins on red blood cells. If incompatible fiery fellow types are of various kinds, the antibodies from one person inclination occasion red blood cells from the other body clump unitedly, by means of devastating results in an emergency. But someone’s immune system usually doesn’cheek by means of jowl make antibodies to the flatter molecules on his or her own red blood cells. That creates a potential blinker spot that bacteria could put to use.

For case in point, a tendency of E. coli (O86) has molecules on its outside like those in humans through lineage type B. People with blood type B are unable to bring into being antibodies for E. coli O86. Although O86 is known to infect birds, it’session not a greater danger like other types of E. coli, some of that can attempt severe diarrhea.

Cummings and his colleagues wanted to know why more bacteria haven’t adopted the tactics of E. coli O86 to get on all sides the immune system. Searching for proteins that could stitch and cover to the sugar molecules distinctive of blood types A and B, graduate students Sean Stowell, PhD, and Connie Arthur identified proteins called galectin-4 and galectin-8.

“These proteins are separate from antibodies and other parts of the immune system,” Cummings says. “They kill bacteria like E. coli O86 all by themselves not beyond a coupling of minutes.”

When E. coli O86 is exposed to these proteins and viewed by electron microscopy, “it looks similar to whether or not person is tearing away at their exterior membranes,” he adds.

However, galectins-4 and -8 did not carry off full of fellow-feeling red blood cells expressing passion collection antigens. High levels of lactose (milk sugar) can inhibit the lethal nimbleness of these galactins, while on the contrary sucrose (cane sugar) does not.

“This raises the debate of whether in that place are dietary effects, taken in the character of from milk sugars or other dietary polysaccharides, that might inhibit activity of these galectins forward intestinal microbes and their proliferation and colonization,” Cummings says.

Cummings notes the unique properties of galectins-4 and -8 may agree every explanation toward why the human population has such a diversity of sugar molecules onward kinship cells. The unlikeness may ensure that some part of the inhabitants power be able to fend off a bacterial infection. For example, ABO blood type seems to act upon susceptivity to Helicobacter pylori, a bacterium linked to ulcers.

Galectins were thought to have evolved long previous to “adaptive immunity,” the part of vertebrates’ immune systems that is responsible for producing a variety of antibodies. Galectins may have allowed the generation of a divergent group of blood type sugar molecules in human tissues as a safe note of molecules to expand because immunity is backstopped by the agency of galectins, Cummings says.

Galectins-4 and-8 were also able to kill any other species of E. coli that display a sugar molecule found onward many mammalian cells, although greater amount of protein was needed. That leads to a question Cummings and his colleagues are investigating things being so: What else do galectins recognize, and to what extent does that inthrall the kinds of bacteria that can live in our intestines? In addition, it may now have being possible, given these results, to engineer molecular changes in these galectins to allow them to kill other types of pathogenic bacteria that display other types of sugar molecules on their surface. Such developments could lead to new types of antibiotics for pathogenic microbes.

The research was supported by the National Institute of General Medical Sciences of the National Institutes of Health and the Consortium in spite of Functional Glycomics and besides involved explanation contributions from Marcelo Dias-Baruffi, PhD, and colleagues at the Universidade de S?o Paolo in Ribeir?o Preto, Brazil.

Reference: S.R. Stowell et al. Innate immune lectins give one his quietus bacteria expressing hot spark group antigen. Nat. Med. 16, page numbers (2010).

Holly Korschun
Emory University

Boy, 3, Born With Half a Heart Waiting for Transplant

February 12th, 2010 -- Posted in Health News | No Comments »

Time is of the essence because of a 3-year-old boy from Utah who was born through a underdone and complex inborn heart want that has essentially left him with half a heart, ABC 4 News reported.

Little Michael Melton suffers from hypoplastic left heart syndrome – a condition in that the left side of his heart is critically underdeveloped. What that resource is that the left side of his heart can’t effectively pump hotspur to the body, according to the Mayo Clinic, so the right side of the heart must cross-question blood both to the lungs and to the rest of the body.

Treatment according to this condition involves one or the other a three-step surgical procedure or a heart transplant, which is exactly the sort of Michael needs.

In order to gain him moved up higher on every voice bestower; donator elect, his mom, Clarissa Melton, moved to the Salt Lake Valley from her hometown of Vernal, Utah.

She’s worried allowing that Michael doesn’familiarily get a transplant soon, he could die.

“I don’familiarily think you can be prepared,” Melton told the word station. “I aim to be. I perceive it would definitely have existence a possibility. It’s probably putting a season limit on my son’s life.”

Michael is generally actuality treated at Primary Children’s Hospital in Salt Lake City.

Click here to understand more and regard a video from ABC 4.

Allegheny General Hospital Study Demonstrates Safety And Potential Efficacy Of Oral Allergy Treatment

February 12th, 2010 -- Posted in Immune System | No Comments »

An oral allergy treatment administered in drops under the dialect is a sure and effective other to injections despite adults who are allergic to ragweed pollen, according to a study published in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General Hospital.

Widely used in Europe, but not yet approved by the U.S. Food and Drug Administration, sublingual allergen immunotherapy (SLIT) can be a more beneficial and tolerable method of treating approach that leads to greater patient compliance, said David Skoner, MD, instructor of AGH’session Division of Allergy, Asthma and Immunology and a co-lead conductor of researches in the examine.

“The study’s tools and materials mark a step front in gaining approval for sublingual president and cabinet of allergy medication,” said Dr. Skoner, “We believe a spacious number of patients would greatly benefit from having access to this of the present day verbal treatment to ease their symptoms.”

“The sublingual method so far has been safe, and the adherence rate should be more valuable because no injections are involved and the medication is administered at domestic,” said co-investigator Deborah Gentile, MD, Director of Research in AGH’s Division of Allergy, Asthma and Immunology.

The AGH study, “Sublingual Immunotherapy in Patients with Allergic Rhinoconjunctivitis Caused by Ragweed Pollen,” involved 115 patients in Pittsburgh, Madison, Wisc., Iowa City and Evansville, Ind. They were randomly assigned to a medium or high drench of standardized glycerinated short ragweed pollen pull out or to a placebo. Participants kept diaries to monitor their symptoms in addition the conduct of 17 weeks for the period of the ragweed pollen accustom.

The frequency of daily symptoms, as well at the same time that the penury for adscititious medication to discuss symptoms, both dropped significantly as being those catching the high-dose medication, versus those taking a placebo. The frequency of unfavorable events was like betwixt the placebo and treatment groups.

The researchers concluded that SLIT was safe and can reduce symptoms in ragweed-sensitive patients, though greater amount of trials are needed to definitively establish the process’s efficacy.

Shortcomings of previous trials through the sublingual method included small patient populations, high withdrawals and brittle method of treating duration. Questions remaining in continuance SLIT include manipulation schedules, optimal doses and cost-effectiveness.

Other researchers involved in the study were Robert Bush, MD of the University of Wisconsin School of Medicine and Public Health; Mary Beth Fasano, MD, University of Iowa Hospitals and Clinics; Anne McLaughlin, MD, of Wellborn Clinical Research Center in Evansville, Ind., and Robert E. Esch, PhD, of Greer Laboratories Inc., Lenoir, NC.

Source: Allegheny General Hospital

Next »